13F Pro Quality Score

48.7/100

Rank #1,708 of 2,961 stocks

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Nov 14, 2026.

Revenue Growth

72.1/100

Profitability

23.2/100

Balance Sheet

24.7/100

Earnings Quality

86.2/100

Free Cash Flow

51.3/100

Institutional Flow

13.3/100

Revenue Scale

47.7/100

Dilution Risk

48.9/100
Email me the moment this company reports earnings
AI Research Report
Two-page plain-English analysis: business, thesis, and three scenarios for the next two years. Refreshed every quarter.
Upgrade to Pro
Pro: 5 reports/month · Pro+: unlimitedOpinion, not investment advice. Do your own research.

Unusual Activity in ECVT

Events flagged as statistical outliers against ECVT's own multi-year baseline — not fixed dollar thresholds.

ECVT Stock Analysis & AI Quality Score

Data updated 2026-09-11

AI stock analysis and institutional research for Ecovyst Inc. (ECVT), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores ECVT at 48.7/100 on a 32-signal composite quality model, placing it at rank #1,708 of 2,961 stocks — the bottom half of the AI-ranked universe. ECVT scores in the top quartile across earnings quality (86.2). Areas of concern include institutional flow (13.3) and profitability (23.2), which score below median versus the broader universe. Shareholder dilution risk is elevated at 48.9/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), Ecovyst Inc. reports quarterly revenue of $250.0M, net income of $7.9M, an operating margin of 7.8%. Top institutional holders of ECVT by reported 13-F value include BlackRock, Rubric Capital Management, DIMENSIONAL FUND ADVISORS, based on the most recent SEC filings. ECVT trades on the NYSE exchange and files with the SEC under CIK 1708035. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate ECVT daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Ecovyst Inc. directly from SEC EDGAR. Ecovyst Inc.'s 13F Pro composite quality score has ranged between 26 and 58 since 2021, currently 48.7 — an improving long-term trajectory across 65 quarterly and live scoring snapshots.

Fun facts about Ecovyst Inc.

Quirks, history, and lore behind ECVT — the kind of stuff that makes a stock memorable.

  • 1
    The Basics
    U.S. specialty chemicals and materials company · listed on the NYSE · headquartered in Malvern, Pennsylvania · small-cap.
  • 2
    The Numbers
    Annual revenue in the range of $500–600 million — not a household name, but quietly essential to refining and industrial processes worldwide.
  • 3
    The History
    The company traces its roots back decades through PQ Group Holdings, which was taken private and later restructured before re-emerging as a focused catalyst and services spinoff around 2021.
  • 4
    The Secret
    Its core business is making silica-based catalysts and providing sulfuric acid regeneration services — unglamorous chemistry that keeps oil refineries running cleanly.
  • 5
    The Lore
    The company rebranded to signal a greener future — the "Eco" in its name nods to sustainability, while its catalyst technology helps refiners produce cleaner fuels with lower emissions.
  • 6
    The Giveaway
    Ticker ECVT, born from the breakup of PQ Group Holdings — a Pennsylvania specialist in zeolyst catalysts and acid regeneration that quietly makes gasoline a little less dirty.
▶ Think you know your stocks? Play the Daily Ticker

Revenue

Q2 2026

$250.0M

Net Income

Q2 2026

$7.9M

Free Cash Flow

Q2 2026

$3.7M

Operating Margin

Q2 2026

7.8%

ROIC

Q2 2026

7.2%

D/E Ratio

Q2 2026

0.84

Period

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro

Revenue

+20.9% YoY
$723.5MFY 2025
FY22 $820.2MFY23 $584.8MFY24 $598.3MFY25 $723.5M

Net Income

-969.2% YoY
$-71.1MFY 2025
FY22 $73.7MFY23 $71.2MFY24 $-6.7MFY25 $-71.1M

Operating Income

-23.8% YoY
$64.9MFY 2025
FY22 $104.4MFY23 $89.6MFY24 $85.1MFY25 $64.9M

EPS (Diluted)

-916.7% YoY
$-0.61FY 2025
FY22 $0.55FY23 $0.60FY24 $-0.06FY25 $-0.61

Total Assets

-30.0% YoY
$1.26BFY 2025
FY22 $1.88BFY23 $1.84BFY24 $1.80BFY25 $1.26B

Total Debt

-54.9% YoY
$392.6MFY 2025
FY22 $883.9MFY23 $876.9MFY24 $869.6MFY25 $392.6M

Op. Cash Flow

-6.4% YoY
$140.3MFY 2025
FY22 $186.6MFY23 $137.6MFY24 $149.9MFY25 $140.3M

Free Cash Flow

-25.9% YoY
$69.9MFY 2025
FY22 $127.7MFY23 $78.6MFY24 $94.3MFY25 $69.9M

Get alerted when ECVT's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for Ecovyst Inc. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)
XBRL financial facts (revenue, EPS, margins)
Insider transactions (Form 4)
Institutional 13F holdings
Quality rankings (32 signals)
AI analyst debates & daily meetings
Historical financial trends
Peer comparison & sector analysis

Top Institutional Holders of ECVT

Companies Similar to ECVT

Ranked by quality-profile closeness and shared hedge-fund ownership — not just sector membership.

COLL

COLLEGIUM PHARMACEUTICAL, INC

63
AI score
Similar quality profile · 11 shared holders
ENOV

Enovis CORP

37
AI score
Similar quality profile · 8 shared holders
INNV

InnovAge Holding Corp.

51
AI score
Similar quality profile · 2 shared holders
PTCT

PTC THERAPEUTICS, INC.

38
AI score
Similar quality profile · 7 shared holders
TVTX

Travere Therapeutics, Inc.

54
AI score
Similar quality profile · 6 shared holders
ATEC

Alphatec Holdings, Inc.

41
AI score
Similar quality profile · 6 shared holders
NVST

Envista Holdings Corp

55
AI score
Similar quality profile · 10 shared holders
STLN

Starling Oncology, Inc.

44
AI score
Similar quality profile · 2 shared holders

Similarity is computed from the 8 composite sub-scores and latest-quarter 13F conviction holdings (index-style filers excluded). Refreshed monthly.

Put ECVT on your watchlist

Track score changes the day Ecovyst Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Is ECVT a good stock to buy?

13F Pro's AI-powered analysis of Ecovyst Inc. (ECVT) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on NYSE). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for ECVT are available on the ECVT stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. ECVT is classified as a small company.

Which hedge funds own ECVT?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling ECVT. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Ecovyst Inc.'s investment landscape.